Dan Grander
Overview
Explore the profile of Dan Grander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
3114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vidarsdottir L, Azimi A, Das I, Sigvaldadottir I, Suryo Rahmanto A, Petri A, et al.
Sci Rep
. 2021 May;
11(1):11023.
PMID: 34040017
BRAF inhibitors (BRAFi) selectively target oncogenic BRAF and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their...
2.
Vidarsdottir L, Fernandes R, Zachariadis V, Das I, Edsbacker E, Sigvaldadottir I, et al.
Melanoma Res
. 2020 May;
30(5):443-454.
PMID: 32467529
Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years. However, only in a subset of the CMM patients,...
3.
Rudd S, Tsesmetzis N, Sanjiv K, Paulin C, Sandhow L, Kutzner J, et al.
EMBO Mol Med
. 2020 Jan;
12(3):e10419.
PMID: 31950591
The deoxycytidine analogue cytarabine (ara-C) remains the backbone treatment of acute myeloid leukaemia (AML) as well as other haematological and lymphoid malignancies, but must be combined with other chemotherapeutics to...
4.
Dyczynski M, Vesterlund M, Bjorklund A, Zachariadis V, Janssen J, Gallart-Ayala H, et al.
Cell Death Dis
. 2018 Aug;
9(9):846.
PMID: 30154400
Glucocorticoids (GCs) are metabolic hormones with immunosuppressive effects that have proven effective drugs against childhood acute lymphoblastic leukemia (ALL). Yet, the role of metabolic reprogramming in GC-induced ALL cell death...
5.
Desroses M, Busker S, Astorga-Wells J, Attarha S, Kolosenko I, Zubarev R, et al.
J Pharm Biomed Anal
. 2018 Aug;
160:80-88.
PMID: 30086509
STAT3 protein is an established target for the development of new cancer therapeutic agents. Despite lacking a traditional binding site for small molecule inhibitors, many STAT3 inhibitors have been identified...
6.
Dyczynski M, Yu Y, Otrocka M, Parpal S, Braga T, Henley A, et al.
Cancer Lett
. 2018 Jul;
435:32-43.
PMID: 30055290
Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance. In this study we systematically screened a library...
7.
Serviss J, Andrews N, Van den Eynden J, Richter F, Houtman M, Vesterlund M, et al.
Cell Death Dis
. 2018 Jul;
9(7):736.
PMID: 29970884
The microRNA-34a is a well-studied tumor suppressor microRNA (miRNA) and a direct downstream target of TP53 with roles in several pathways associated with oncogenesis, such as proliferation, cellular growth, and...
8.
Serviss J, Gadin J, Eriksson P, Folkersen L, Grander D
Bioinformatics
. 2017 Sep;
33(19):3126-3128.
PMID: 28957498
Summary: Multi-dimensional data generated via high-throughput experiments is increasingly used in conjunction with dimensionality reduction methods to ascertain if resulting separations of the data correspond with known classes. This is...
9.
Lister N, Shevchenko G, Walshe J, Groen J, Johnsson P, Vidarsdottir L, et al.
Proc Natl Acad Sci U S A
. 2017 Aug;
114(37):9942-9947.
PMID: 28847966
RNA has been found to interact with chromatin and modulate gene transcription. In human cells, little is known about how long noncoding RNAs (lncRNAs) interact with target loci in the...
10.
Kolosenko I, Edsbacker E, Bjorklund A, Hamil A, Goroshchuk O, Grander D, et al.
J Control Release
. 2017 Jul;
261:199-206.
PMID: 28684168
Epidemiological studies of childhood leukemia survivors reveal an alarmingly high incidence of chronic health disabilities after treatment, therefore, more specific therapies need to be developed. Polo-like kinase 1 (Plk1) is...